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Abstract
Objective Identifying potentially modifiable risk factors for ovarian cancer is essential for prevention because this cancer is 
predominantly detected at a late stage. Here, we estimated the relations of general adiposity and measures reflecting body 
fat distribution to the risk of epithelial ovarian cancer.
Methods We ascertained 683 ovarian epithelial cancers (343 high-grade serous, 141 non-high grade serous) among 145,575 
women, aged 50–72 years (median follow-up 12.6 years), from the National Institutes of Health—American Association of 
Retired Persons (NIH-AARP) Diet and Health Study. Using Cox models, we estimated confounder-adjusted hazard ratios 
(HRs) and 95% confidence intervals (CI) for associations of overall ovarian cancer, high-grade serous and non-high-grade 
serous carcinoma with body mass index, waist circumference, hip circumference, waist–hip ratio, waist–height ratio, body 
adiposity index, body shape index, and abdominal volume index.
Results Anthropometric measures were unrelated to overall ovarian cancer, high-grade serous cancer, and non-high-grade 
serous cancer. For example, the HR for overall ovarian cancer per standard deviation increment of body mass index at baseline 
was 0.98 (95% CI 0.88–1.10). Similar associations were observed with measurements of body fat distribution.
Conclusion These results do not indicate that adult adiposity is associated with ovarian cancer risk in post-menopausal 
women.
Keywords Adiposity · Body fat · Obesity · Ovarian cancer risk
Introduction
Ovarian cancer is the fifth most common cause of cancer 
death in women in North America and western Europe [1]. 
Meta-analyses and pooled observational studies suggest 
that obesity may be positively related to ovarian cancer risk 
[2–5]. The World Cancer Research Fund/American Institute 
for Cancer Research concluded that the evidence for the link 
between obesity and increased ovarian cancer risk is prob-
able [6], and an umbrella review graded the evidence as sug-
gestive [3]. A growing body of research further suggests that 
body composition plays an important role in site-specific 
cancer development [7–9]. Previous studies indicate that 
anthropometric measures of general obesity and body fat 
distribution may be differentially related to ovarian cancer 
risk; however, results have been conflicting [4, 5, 10–12]. We 
conducted a cohort study among post-menopausal women 
using data from the National Institutes of Health-Ameri-
can Association of Retired Persons (NIH-AARP) Diet and 
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Health Study to provide further insights into the association 
between body fatness and subtype-specific epithelial ovarian 




The NIH-AARP Diet and Health Study is a prospec-
tive cohort study of persons in the U.S. [13]. At base-
line (1995–1996), 3.5 million AARP members aged 
50–71 years who resided in six states (California, Florida, 
Louisiana, New Jersey, North Carolina, and Pennsylvania) 
and  two metropolitan areas (Atlanta, Georgia; and Detroit, 
Michigan) were invited to complete a questionnaire on 
demographic, diet, and lifestyle characteristics. Ques-
tionnaires were completed satisfactorily by 566,398 par-
ticipants. Six months after completing the baseline ques-
tionnaire, a second questionnaire was mailed to living 
participants who did not have a self-reported colon, breast, 
or prostate cancer at baseline to collect additional informa-
tion. Self-reported weight and height were collected on the 
baseline questionnaire. Self-reported waist circumference 
and hip circumference were assessed on the second ques-
tionnaire. We excluded male participants (n = 339,666); 
those with unknown cancer or previous diagnosis of cancer 
other than non-melanoma skin cancer at baseline before 
completion of the second questionnaire (n = 16,300); 
those with bilateral oophorectomy and unknown oopho-
rectomy status (n = 57,047); those with no information on 
height, weight, waist circumference, or hip circumference 
(n = 95,764); and subjects with body mass index less than 
18.5 kg/m2 or more than 65 kg/m2 (n = 3,528). Our final 
analytical datasets included 145,575 women for the analy-
sis on body mass index, 60,999 for waist circumference, 
60,826 for hip circumference, 60,597 for waist-to-hip ratio, 
60,999 for waist-to-height ratio, 60,826 for body adipos-
ity index, 60,999 for body shape index, and 60,597 for 
abdominal adiposity index. The Special Studies Institu-
tional Review Board of the U.S. National Cancer Institute 
approved the study [13]. All participants gave informed 
consent by virtue of completing and returning the baseline 
questionnaire.
Assessment of anthropometric measures
Self-reported height and weight were obtained from the 
baseline questionnaire. Body mass index was calculated as 
weight (kg) divided by the square of height (in meters). In 
the second questionnaire, participants were instructed to 
measure their waist circumference and hip circumference 
using a tape measure to the nearest 0.25 inch while stand-
ing. Waist circumference was to be measured 1 inch above 
the navel if this was not the waistline. Hip circumference 
was defined as the largest circumference between the upper 
edge of the pelvis and the femur. Waist–hip ratio was calcu-
lated by dividing waist circumference (cm) by hip circum-
ference (cm), and waist–height ratio was calculated as waist 
circumference (cm)/height (cm). The body adiposity index 
was calculated as hip circumference (cm)∕height1.5(m) − 18 
[14] .  The body shape index was  based on 
waist circumference (cm)∕body mass index
2
3 × height2(m) 
[15]. The abdominal volume index was also quantified [16]:
Definition of cancer outcomes
Diagnoses of ovarian cancer were ascertained through 31 
September 2011, via linkage to state cancer registries of 
the eight recruitment areas where the study participants 
were most likely to relocate: Arizona, Nevada, and Texas. 
This approach has been estimated to yield a sensitivity of 
90% and a specificity of nearly 100% [17]. Newly diag-
nosed ovarian cancer cases were identified using the Inter-
national Classification of Diseases for Oncology (ICD-
O-3), topography (C56.9), and morphology codes (8441, 
8460, 8461, 8470, 8471, 8480, 8481, 8380, 8381, 8560, 
8570, 8310, 8313, 8010, 8020, 8021, 8050, 8070, 8120, 
8140, 8255, 8260, 8323, 8440, 8450, 8562, 9000) [18]. 
The high-grade serous group included all invasive serous 
cancers except low grade [19, 20]. The non-high-grade 
group included all serous cancers and invasive mucinous, 
endometrial, and clear cell cancers [20]. Borderline tumors 
were excluded from this study.
Baseline confounders
We controlled for several baseline participant characteris- 
tics that were assumed to cause adiposity or ovarian cancer 
[3, 5, 21–23]. We assumed that direct causes of the expo-
sure or outcome, excluding possible instrumental variables, 
would identify a sufficient set of confounders [24]. Potential 
confounding variables included age, education (no school 
(2 cm × waist circumference2 (cm) + 0.7 cm × (waist circumference (cm) − hip circumference (cm))2)∕1,000.
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degree/unknown, primary school, technical school/second-
ary, university), participants’ self-reported information on 
race/ethnicity (none-Hispanic white, other), cigarette smok-
ing (never, current < 15 cigarettes per day, current ≥ 15 cig-
arettes/day, former < 10 years, former ≥ 10 years), alcohol 
consumption (in grams of pure alcohol per day), parity (0, 
1, ≥ 2 children), age at menarche (≤ 12 years, > 12 years), 
family history of ovarian cancer, oral contraceptive use, and 
menopausal hormone therapy.
Statistical analysis
Cox proportional hazards regression was used for esti-
mating adjusted hazard ratios (HRs) and 95% confidence 
intervals (CIs) for overall ovarian cancer and ovarian 
cancer subtypes. Time of study entry was age at base-
line (or second questionnaire) and exit time was age at 
cancer diagnosis or the last date at which follow-up was 
considered complete. Athropometric measures were mod-
eled as a continuous and categorical metric. After con-
firming that the linearity assumption was met by testing 
cubic spline transformations [25], HRs were estimated 
per standard deviation (1-SD) increase in anthropometric 
measures. Body mass index (kg/m2) was further grouped 
as normal weight (18.5 to < 25), overweight (25 to < 30), 
and obese (≥ 30). Waist circumference and other anthropo-
metric measures were categorized according to quartiles. 
Models were stratified by 5-year age groups to minimize 
departure from proportionality and adjusted for education, 
race, smoking, alcohol consumption (modeled continu-
ously using restricted cubic splines [25]), parity, age at 
menarche, family history of ovarian cancer, oral contra-
ceptive use, and menopausal hormone therapy.
The improvement in predictive accuracy after adding 
anthropometric measures to a null model (including race, 
age, education, smoking, alcohol consumption, parity, family 
history of ovarian cancer, oral contraceptive use and meno- 
pausal hormone therapy) was evaluated in terms of explained 
variation (R2) [26], the Bayes Information Criterion (BIC), 
and model discrimination using Harrell’s C-index [25] 
derived from flexible parametric models [27]. p values for 
the difference between Harrell’s C indices of models with 
and without anthropometric indicators were computed using 
the method proposed by Antolini et al. [28]. We used 1,000 
bootstrap replications to perform internal validations and to 
correct R2, BIC, and Harrell’s C-indices for optimism [25].
In a sensitivity analysis, we used regression calibra-
tion for self-reported body mass index, waist circumfer-
ence, and hip circumference to assess possible regression 
dilution bias [29]. Because replicate measurements were 
not available, we applied published reliability coeffi- 
cients [30–33], ranging from 0.5 to 0.9. A further threat 
to the validity of our estimates is potential unobserved 
confounding by undiagnosed ovarian cancer (often referred 
to as “reverse causation” [34]) if these conditions are 
symptomatic enough to induce a change in body weight. 
We, therefore, assumed 3 years of minimum latent period 
required for weight change due to unobserved disease to 
affect the outcome and excluded events that occurred dur-
ing this time [35]. The statistical analysis was performed 
using Stata 15.1.
Results
In the analytical sample of 145,575 women, the mean (SD) 
age at baseline was 61.8 (5.4) years. During a median follow-
up time of 12.6 years, participants contributed 1,897,323 
person-years and 683 ovarian cancer (343 high-grade serous) 
cases occurred. The baseline characteristics of the analytical 
sample are provided in Table 1.
Neither body mass index nor other anthropometric meas-
urements were associated with the risk of ovarian cancer 
(Table 2). For example, HRs for overall ovarian cancer per 
1-SD increment in body mass index, waist circumference, 
hip circumference, waist–hip ratio, and waist–height ratio 
were 0.98 (95% CI 0.88–1.10), 1.08 (95% CI 0.91–1.27), 
1.06 (95% CI 0.90–1.25), 1.03 (95% CI 0.89–1.21), and 
1.08 (95% CI 0.92–1.27), respectively. In categorical analy-
ses, the HRs for comparing obese and normal weight body 
mass index groups, and the highest and lowest quartiles of 
waist circumference, hip circumference, waist–hip ratio, and 
waist–height ratio were 1.11 (95% CI 0.91–1.36), 1.17 (95% 
CI 0.84–1.62), 1.28 (95% CI 0.94–1.75), 1.35 (95% CI 0.97; 
1.89), and 1.18 (95% CI 0.85–1.64), respectively. No associ-
ations were observed for high-grade serous carcinomas. The 
accuracy of models predicting ovarian cancer risk was not 
improved after adding anthropometric measures (Table 3).
Sensitivity analysis indicated that HRs could have been 
attenuated towards the null because of measurement error 
in self-reported anthropometric measurements. For exam-
ple, the unadjusted HR for per SD of waist circumference 
and overall ovarian cancer was 1.08 (95% CI 0.91–1.27), 
but after accounting for potential regression dilution bias, 
assuming an attenuation factor of 0.7, the HR was 1.11 (95% 
CI 0.91–1.30) (Supplementary Table 1). The associations 
were virtually unchanged when events occurring during the 
first three years of follow-up were excluded (Supplementary 
Table 2).
Discussion
This study examined the association of indicators of gen-
eral obesity and body fat distribution with ovarian can-
cer risk using a large U.S. prospective cohort study of 
234 Cancer Causes & Control (2021) 32:231–239
1 3
Table 1  Baseline characteristics of ovarian cancer cases among 145,575 women in the NIH-AARP Study
All study subjects No ovarian cancer Ovarian cancer Histological subtypes
High-grade serous Non-high-grade serous
Age (years) 61.8 (5.4) 61.8 (5.4) 62.7 (5.4) 62.4 (5.4) 61.9 (5.7)
Education (n (%))
 < 12 years 8,259 (5.6) 8,223 (5.6) 36 (5.1) 11 (3.1) 7 (4.8)
 12 years 37,549 (25.6) 37,374 (26.6) 175 (24.9) 85 (24.2) 43 (29.4)
 > 12 years 100,736 (68.7) 100,243 (68.7) 493 (70.0) 255 (72.7) 96 (65.8)
Race (n (%))
 Non-hispanic white 137,456 (91.2) 136,763 (91.3) 693 (94.93) 355 (96.2) 141 (94.6)
 Non-hispanic black 7,883 (7.9) 7,864 (5.3) 19 (2.6) 4 (1.1) 6 (4.0)
 Hispanic/other 5,199 (5.2) 5,181 (3.5) 18 (2.5) 10 (2.7) 2 (1.3)
Body mass index (kg/m2) 26.8 (5.5) 26.8 (5.5) 26.7 (5.5) 26.2 (4.8) 26.4 (5.2)
 18.5 to < 25 (n (%)) 67,266 (44.7) 66,936 (44.7) 330 (45.2) 179 (48.5) 64 (43.0)
 25 to < 30 (n (%)) 49,207 (32.7) 48,979 (32.2) 228 (31.2) 115 (31.2) 53 (35.6)
 30+ (n (%)) 34,065 (22.6) 33,893 (22.6) 172 (23.6) 75 (20.3) 32 (21.5)
Waist circumference (cm) 84.6 (13.2) 84.6 (13.2) 85.3 (13.2) 84.0 (11.6) 86.6 (15.8)
 Quartile 1 (n (%)) 15,346 (25.0) 15,268 (24.4) 78 (25.2) 40 (25.1) 16 (28.8)
 Quartile 2 (n (%)) 16,600 (25.0) 16,533 (26.5) 67 (21.6) 41 (25.8) 5 (8.9)
 Quartile 3 (n (%)) 15,618 (25.0) 15,538 (24.9)) 80 (25.8) 41 (25.8) 17 (30.4)
 Quartile 4 (n (%)) 15,247 (25.0) 15,162 (24.3) 85 (27.4) 37 (23.3) 18 (32.1)
Hip circumference (cm) 103.9 (11.5) 103.9 (11.5) 104.5 (11.4) 103.4 (10.2) 104.3 (11.9)
 Quartile 1 (n (%)) 19,006 (25.0) 18,919 (30.4) 87 (28.1) 49 (31.0) 14 (25.0)
 Quartile 2 (n (%)) 13,197 (25.0) 13,128 (21.1) 69 (22.3) 37 (23.4) 11 (19.6)
 Quartile 3 (n (%)) 15,192 (25.0) 15,126 (24.3 66 (21.3) 33 (20.9) 12 (21.4)
 Quartile 4 (n (%)) 15,231 (25.0) 15,143 (24.3) 88 (28.4) 29 (24.7) 19 (33.9)
Waist–hip ratio 0.81 (0.08) 0.81 (0.08) 0.81 (0.08) 0.81 (0.07) 0.81 (0.09)
 Quartile 1 (n (%)) 15,525 (25.0) 15,454 (24.9) 71 (22.9) 35 (22.2) 17 (30.4)
 Quartile 2 (n (%)) 15,704 (25.0) 15,628 (25.2) 76 (24.6) 44 (27.9) 7 (12.5)
 Quartile 3 (n (%)) 15,833 (25.0) 15,755 (25.4) 78 (25.2) 40 (25.3) 13 (23.2)
 Quartile 4 (n (%)) 15,317 (25.0) 15,233 (24.5) 84 (27.2) 39 (24.7) 19 (33.9)
Waist–height ratio 0.52 (0.08) 0.51 (0.08) 0.52 (0.0.8) 0.51 (0.07) 0.52 (0.10)
 Quartile 1 (n (%)) 15,360 (25.0) 15,283 (24.5) 77 (24.8) 36 (22.6) 17 (30.4)
 Quartile 2 (n (%)) 16,183 (25.0) 16,116 (25.8) 67 (21.6) 40 (25.2) 7 (12.5)
 Quartile 3 (n (%)) 15,811 (25.0) 15,731 (25.2) 80 (25.8) 45 (28.3) 14 (25.0)
 Quartile 4 (n (%)) 15,457 (25.0) 15,371 (24.6) 86 (27.7) 38 (23.9) 18 (32.1)
Body adiposity index 31.9 (5.8) 31.8 (5.8) 32.2 (6.0) 31.7 (5.3) 32.1 (5.9)
 Quartile 1 (n (%)) 15,045 (25.0) 14,976 (24.0) 69 (22.3) 34 (21.5) 11 (19.6)
 Quartile 2 (n (%)) 16,882 (25.0) 16,800 (27.0)) 82 (26.5) 51 (32.3) 11 (19.6)
 Quartile 3 (n (%)) 15,524 (25.0) 15,445 (24.8) 79 (25.5) 40 (25.3) 20 (35.7)
 Quartile 4 (n (%)) 15,175 (25.0) 15,095 (24.2) 80 (25.8) 33 (20.9) 14 (25.0)
Body shape index 0.01 (0.003) 0.01 (0.003) 0.01 (0.003) 0.01 (0.003) 0.01 (0.003)
 Quartile 1 (n (%)) 15,302 (25.0) 15,226 (24.4) 76 (24.5) 33 (20.8) 13 (23.2)
 Quartile 2 (n (%)) 15,958 (25.0) 15,884 (25.4) 74 (23.9) 36 (22.6) 17 (20.4)
 Quartile 3 (n (%)) 16,294 (25.0) 16,212 (25.9) 82 (26.5) 46 (28.9) 18 (32.1)
 Quartile 4 (n (%)) 15,257 (25.0) 15,179 (24.3) 78 (25.2) 44 (27.7) 8 (14.3)
Abdominal volume index 15.0 (4.7) 15.0 (4.7) 15.2 (4.6) 14.7 (3.9) 15.5 (5.4)
 Quartile 1 (n (%)) 15,317 (25.0) 15,237 (24.6) 80 (25.9) 41 (26.0) 16 (28.6)
 Quartile 2 (n (%)) 16,005 (25.0) 15,942 (25.7) 63 (20.4) 39 (24.7) 5 (8.9)
 Quartile 3 (n (%)) 15,711 (25.0) 15,632 (25.2) 79 (25.6) 39 (24.7) 17 (30.4)
 Quartile 4 (n (%)) 15,346 (25.0) 15,259 (25.6) 87 (28.2) 39 (24.7) 18 (32.1)
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post-menopausal women. We found no association of 
anthropometric measures with the risk of overall ovarian 
cancer, high-grade serous, or non-high-grade ovarian can-
cers. Overall, our analysis does not support the hypothesis 
that central adiposity or measures of body fat distribution 
improve the prediction of ovarian cancer risk in post-men-
opausal women.
A larger body of research examined the association 
between obesity and ovarian cancer risk. However, the 
findings of more than 30 epidemiologic studies have been 
weak and mixed [36]. Several meta-analyses and pooled 
analyses reported weak positive associations between adult 
body mass index and ovarian cancer risk, noting substantial 
between-study heterogeneity with weaker associations in 
prospective than case–control studies [2, 6, 37]. A system-
atic review from the World Cancer Research Fund and the 
American Institute for Cancer Research included 28 pro-
spective studies on ovarian cancer and calculated a summary 
relative risk for a 5-unit increment in body mass index of 
1.07 (95% CI 1.03–1.11) [2, 6]. The effect size was similar 
in the post-menopausal group but it was less precise (rela-
tive risk per 5 kg m−2 = 1.07; 95% CI 1.00–1.14). Results 
from the 2013 Ovarian Cancer Association Consortium [4] 
pooled analysis of case–control studies found that the posi-
tive association with body mass index was stronger in pre-
menopausal women. The heterogeneity of findings reported 
here and previously could be explained by menopausal status 
and higher statistical efficacy of meta-analysis. Indeed, our 
HRs for body mass index and waist circumference overlap 
with the HR’s CIs of the World Cancer Research Fund/
American Institute for Cancer Research meta-analysis [2, 
6], which indicates that there might be chance variation of 
estimates. Few studies have examined how different meas-
ures of body fat distribution are related to ovarian cancer 
and its subtypes [10–12]. Existing cohort studies found no 
association of waist circumference and waist–hip ratio and 
ovarian cancer risk [2, 6, 10]. Similar to previous studies [4, 
5], the present study found no notable differences between 
histotypes. In contrast, a Mendelian randomization study 
suggested that obesity might cause non-high-grade but not 
high-grade ovarian cancer [20].
The present study has several limitations. It relied on 
self-reported anthropometric data and potential measure-
ment error could have attenuated the observed associations. 
Anthropometric measurements were taken when most study 
participants had reached menopause. However, pre-meno-
pausal anthropometric risk factors might be more strongly 
related to ovarian cancer risk. A Mendelian randomization 
study suggested a positive association with higher body 
mass index with risk of ovarian cancer among pre-meno- 
pausal women, but not for post-menopausal women [38]. 
Unfortunately, we could not test whether the association 
between anthropometric markers and ovarian cancer risk 
was modified by menopause status. More studies on body 
Table 1  (continued)
All study subjects No ovarian cancer Ovarian cancer Histological subtypes
High-grade serous Non-high-grade serous
Smoking status (n (%))
 Never smoked 68,479 (45.5) 68,118 (45.5) 361 (49.5) 202 (54.7) 64 (42.9)
 Former smoker, ≤ 20 cigarettes per day 41,527 (27.6) 41,323 (27.6) 204 (27.9) 87 (23.6) 56 (37.6)
 Former smoker, > 20 cigarettes per day 18,884 (12.5 18,803 (12.6) 81 (11.1) 38 (10.5) 14 (9.4)
 Current smoker, ≤ 20 cigarettes per day 15,774 (10.5 15,709 (10.5) 65 (8.8) 33 (8.9) 14 (9.4)
 Current smoker, > 20 cigarettes per day 5,874 (3.9) 5,855 (3,9) 19 (2.6) 9 (2.4) 1 (0.7)
Alcohol consumption (g/day) 6.2 (17.3) 6.2 (17.3) 6.0 (14.7) 5.4 (9.8) 5.5 (13.4)
Parity (n (%))
 Never had a child 22,954 (15.3) 22,819 (5.3) 135 (18.5) 63 (17.1) 39 (26.4)
 1 child 15,342 (10.2) 15,255 (10.3) 87 (11.9) 44 (11.9) 18 (12.2)
 2 and more children 111,501 (74.4) 110,994 (74.4) 507 (69.4) 262 (70.0) 91 (51.5)
Age at menarche (n (%))
 ≤ 12 years 72,734 (48.5) 72,375 (48.5) 359 (49.4) 191 (51.8) 67 (45.6)
 > 12 years 77,150 (51.5) 76,782 (51.5) 368 (50.6) 178 (48.2) 80 (54.4)
Family history of ovarian cancer (n (%)) 9,154 (6.1) 9,101 (6.1) 53 (7.3) 22 (5.9) 13 (8.7))
Ever oral contraceptive use (n (%)) 60,739 (40.7) 60,500 (40.6) 239 (33.1) 115 (31.3) 64 (43.2)
Ever hormone replacement therapy (n 
(%))
69,739 (46.3) 69,370 (46.3) 369 (50.6) 201 (54.5) 70 (47.0)
NIH-AARP, NIH-AARP Diet and Health Study. Entries are means (standard deviation) for continuous variables and percent values for categori-
cal variables
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Table 2  Association of general obesity and indicators of body fat distribution with ovarian cancer in NIH-AARP
Ovarian cancer risk High-grade serous Non-high-grade serous
Body mass index (n = 145,575), number of cases 683 343 141
HR per SD (95% CI) 0.98 (0.88; 1.10) 0.91 (0.77; 1.08) 0.92 (0.71; 1.19)
HR, categorical
 18.5 to < 25 (n (%)) Reference Reference Reference
 25 to < 30 (n (%)) 0.97 (0.81; 1.16) 0.94 (0.73; 1.20) 1.13 (0.77; 1.65)
 ≥ 30 (n (%)) 1.11 (0.91; 1.36) 0.91 (0.68; 1.22) 1.03 (0.65; 1.63)
 Joint p value 0.418 0.772 0.814
Waist circumference (n = 60,999), number of cases 295 151 54
HR per SD (95% CI) 1.08 (0.91; 1.27) 1.00 (0.79; 1.27) 1.10 (0.76; 1.60)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 0.82 (0.59; 1.16) 1.09 (0.69; 1.70) 0.30 (0.11; 0.81)
 Quartile 3 1.06 (0.76; 1.46) 1.16 (0.74; 1.84) 0.97 (0.48; 1.99)
 Quartile 4 1.17 (0.84; 1.62) 1.07 (0.66; 1.73) 1.22 (0.61; 2.47)
 Joint p value 0.226 0.932 0.099
Hip circumference (n = 60,826), number of cases 295 150 54
HR per SD (95% CI) 1.06 (0.90; 1.25) 0.98 (0.77; 1.24) 1.02 (0.70; 1.49)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 1.07 (0.77; 1.48) 1.07 (0.69; 1.66) 1.13 (0.51; 2.50)
 Quartile 3 0.91 (0.65; 1.27) 0.83 (0.52; 1.31) 1.00 (0.45; 2.20)
 Quartile 4 1.28 (0.94; 1.75) 1.06 (0.68; 1.65) 1.67 (0.81; 3.43)
 Joint p value 0.203 0.712 0.448
Waist–hip ratio (n = 60,597), number of cases 294 150 54
HR per SD (95% CI) 1.03 (0.89; 1.21) 1.03 (0.82; 1.29) 1.02 (0.70; 1.49)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 1.16 (0.83; 1.63) 1.44 (0.91; 2.28) 0.38 (0.15; 0.98)
 Quartile 3 1.15 (0.82; 1.61) 1.22 (0.75; 1.97) 0.84 (0.40; 1.76)
 Quartile 4 1.35 (0.97; 1.89) 1.38 (0.85; 2.24) 1.31 (0.66; 2.61)
 Joint p value 0.362 0.435 0.069
Waist–height ratio (n = 60,999), number of cases 295 151 54
HR per SD (95% CI) 1.08 (0.92; 1.27) 1.00 (0.79; 1.27) 1.13 (0.78; 1.64)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 0.86 (0.61; 1.20) 1.22 (0.76; 1.94 0.35 (0.14; 0.89)
 Quartile 3 1.06 (0.76; 1.47) 1.42 (0.89; 2.25) 0.80 (0.38; 1.67)
 Quartile 4 1.18 (0.85; 1.64) 1.22 (0.74; 2.00) 1.16 (0.58; 2.33)
 Joint p value 0.304 0.530 0.080
Body adiposity index (n = 60,826), number of cases 294 150 54
HR per SD (95% CI) 1.07 (0.91; 1.26) 0.98 (0.77; 1.25) 1.06 (0.76; 1.55)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 1.00 (0.72; 1.39) 1.33 (0.85; 2.08) 0.92 (0.40; 2.13)
 Quartile 3 1.06 (0.76; 1.48) 1.13 (0.70; 1.82) 1.78 (0.84; 3.77)
 Quartile 4 1.14 (0.81; 1.48) 0.99 (0.59; 1.65) 1.27 (0.55; 2.93)
 Joint p value 0.850 0.508 0.279
Body shape index (n = 60,999), number of cases 294 151 54
HR per SD (95% CI) 0.98 (0.83; 1.16) 1.08 (0.85; 1.36) 0.82 (0.55; 1.21)
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weight and body fatness changes over the lifecourse are 
warranted [39, 40]. Our study also lacked updated infor-
mation on anthropometric measurements during follow-up. 
Another drawback is the low number of cases by ovarian 
cancer subtype and a lack of statistical power to test for 
effect modification.
Table 2  (continued)
Ovarian cancer risk High-grade serous Non-high-grade serous
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 0.84 (0.60; 1.17) 0.92 (0.56; 1.50) 1.16 (0.55; 2.44)
 Quartile 3 0.94 (0.68; 1.30) 1.18 (0.74; 1.88) 1.17 (0.56; 2.46)
 Quartile 4 0.93 (0.67; 1.30) 1.20 (0.75; 1.93) 0.56 (0.23; 1.40)
 Joint p value 0.787 0.611 0.342
Abdominal volume index (n = 60,597), number of cases 295 150
HR per SD (95% CI) 1.07 (0.91;1.25) 0.98 (0.77; 1.25) 1.13 (0.79; 1.61)
HR, categorical
 Quartile 1 Reference Reference Reference
 Quartile 2 0.78 (0.55; 1.10) 1.04 (0.66; 1.63) 0.31 (0.11; 0.84)
 Quartile 3 1.00 (0.73; 1.39) 1.06 (0.67; 1.68) 0.96 (0.47; 1.97)
 Quartile 4 1.15 (0.83; 1.59) 1.09 (0.68; 1.74) 1.21 (0.60; 2.44)
 Joint p value 0.155 0.988 0.061
NIH-AARP, NIH-AARP Diet and Health Study. HR (hazard ratio) from age-group stratified multivariable Cox model adjusted for education, 
race, smoking, alcohol consumption, parity, age at menarche, family history of ovarian cancer, oral contraceptive use, and menopausal hormone 
therapy. Joint p value from Wald test of all exposure dummy variables
Table 3  General obesity and indicators of body fat distribution for prediction of ovarian cancer
Null model included the predictor’s age, education, race, smoking, alcohol consumption, physical activity, parity, family history of ovarian can-
cer, family history of breast cancer, hormone therapy. Adjusted R2: explained variation























0.059 0.059 0.071 0.068 0.066 0.072 0.068 0.069 0.068








0.099 0.100 0.1337 0.126 0.127 0.134 0.135 0.112 0.126








0.089 0.089 0.064 0.069 0.064 0.062 0.053 0.060 0.061




0.65 0.66 (0.643) 0.64 (0.213) 0.64 (0.193) 0.64 (0.164) 0.64 (0.186) 0.65 (0.094) 0.65 (0.124) 0.65 (0.208)
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In summary, results from this prospective study of post-
menopausal women do not support associations between 
measures of central obesity and body fat distribution and 
risk of ovarian cancer.
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